PURPOSE: Local therapy for patients with nonspine bone metastases is evolving, with data supporting the use of single-fraction treatments, and more recently, showing possible benefit from stereotactic body radiation therapy (SBRT). However, the rate of local salvage therapy (LST) after each technique has not been characterized in real-world clinic settings where patients are selected at physician discretion. We examined rates of LST in patients with nonspine bone metastases. METHODS AND MATERIALS: We reviewed records of RT for nonspine bone metastases at our institution from January 1, 2016, to December 31, 2018. We defined LST as the first occurrence of RT or surgery for oncologic progression to a bone metastasis after initial RT. Cumulative incidence functions for retreatment were generated. We conducted multivariate analysis to identify variables associated with LST. RESULTS: A total of 1754 patients were analyzed, with median follow-up of 16.2 months (range, 0-36.8 months). Of all episodes of RT, 51.5% were multifraction external beam radiation therapy (EBRT), 7.0% were single-fraction EBRT, and 41.4% were SBRT. Altogether, 88 patients (5.0%) required LST, with an incidence at 6 months of 2.5%. Incidence of LST at 6 months was 2.1% for SBRT, 5.3% for single-fraction conventional regimens, and 2.4% for multifraction conventional regimens (P = .26). Patients of younger age, who had a higher Karnofsky performance status, and/or who had lesions in the pelvis had a higher risk of retreatment. CONCLUSIONS: In this large institutional cohort, the rate of LST was low, with no difference between RT techniques. The findings indicated that SBRT for patients at high risk for treatment failure may reduce the rate of retreatment overall. When treatment modality was selected based on patient characteristics, rates of LST were lower than when treatment was randomly selected.
PURPOSE: Local therapy for patients with nonspine bone metastases is evolving, with data supporting the use of single-fraction treatments, and more recently, showing possible benefit from stereotactic body radiation therapy (SBRT). However, the rate of local salvage therapy (LST) after each technique has not been characterized in real-world clinic settings where patients are selected at physician discretion. We examined rates of LST in patients with nonspine bone metastases. METHODS AND MATERIALS: We reviewed records of RT for nonspine bone metastases at our institution from January 1, 2016, to December 31, 2018. We defined LST as the first occurrence of RT or surgery for oncologic progression to a bone metastasis after initial RT. Cumulative incidence functions for retreatment were generated. We conducted multivariate analysis to identify variables associated with LST. RESULTS: A total of 1754 patients were analyzed, with median follow-up of 16.2 months (range, 0-36.8 months). Of all episodes of RT, 51.5% were multifraction external beam radiation therapy (EBRT), 7.0% were single-fraction EBRT, and 41.4% were SBRT. Altogether, 88 patients (5.0%) required LST, with an incidence at 6 months of 2.5%. Incidence of LST at 6 months was 2.1% for SBRT, 5.3% for single-fraction conventional regimens, and 2.4% for multifraction conventional regimens (P = .26). Patients of younger age, who had a higher Karnofsky performance status, and/or who had lesions in the pelvis had a higher risk of retreatment. CONCLUSIONS: In this large institutional cohort, the rate of LST was low, with no difference between RT techniques. The findings indicated that SBRT for patients at high risk for treatment failure may reduce the rate of retreatment overall. When treatment modality was selected based on patient characteristics, rates of LST were lower than when treatment was randomly selected.
Authors: Paulien G Westhoff; Alexander de Graeff; Evelyn M Monninkhof; Laurens Bollen; Sander P Dijkstra; Elzbieta M van der Steen-Banasik; Marco van Vulpen; Jan Willem H Leer; Corrie A Marijnen; Yvette M van der Linden Journal: Int J Radiat Oncol Biol Phys Date: 2014-09-24 Impact factor: 7.038
Authors: Tanja Sprave; Vivek Verma; Robert Förster; Ingmar Schlampp; Thomas Bruckner; Tilman Bostel; Stefan Ezechiel Welte; Eric Tonndorf-Martini; Nils Henrik Nicolay; Jürgen Debus; Harald Rief Journal: Radiother Oncol Date: 2018-05-26 Impact factor: 6.280
Authors: William F Hartsell; Charles B Scott; Deborah Watkins Bruner; Charles W Scarantino; Robert A Ivker; Mack Roach; John H Suh; William F Demas; Benjamin Movsas; Ivy A Petersen; Andre A Konski; Charles S Cleeland; Nora A Janjan; Michelle DeSilvio Journal: J Natl Cancer Inst Date: 2005-06-01 Impact factor: 13.506
Authors: David D Howell; Jennifer L James; William F Hartsell; Mohan Suntharalingam; Mitchell Machtay; John H Suh; William F Demas; Howard M Sandler; Lisa A Kachnic; Lawrence B Berk Journal: Cancer Date: 2012-11-16 Impact factor: 6.860
Authors: M Maltoni; M Pirovano; E Scarpi; M Marinari; M Indelli; E Arnoldi; M Gallucci; L Frontini; L Piva; D Amadori Journal: Cancer Date: 1995-05-15 Impact factor: 6.860
Authors: Erin F Gillespie; Kaitlyn Lapen; Diana G Wang; N Wijetunga; Gerri L Pastrana; Marisa A Kollmeier; Josh Yamada; Adam M Schmitt; Daniel S Higginson; Max Vaynrub; Ernesto Santos Martin; Amy J Xu; C Tsai; Divya Yerramilli; Oren Cahlon; T Yang Journal: Clin Transl Radiat Oncol Date: 2020-10-08